ABBV — Patent Expiration for UBRELVY (US11717515)
Dec 22, 2041, 12:00:00 AM UTC
Summary
Patent US11717515 for UBRELVY, owned by ABBVIE INC and Allergan Pharmaceuticals International Ltd, is set to expire on December 22, 2041. This patent covers methods for the acute treatment of migraines using ubrogepant, including considerations for patients with hepatic and renal impairments, as well as those on specific medication interactions. The expiration may allow for increased competition in the migraine treatment market, potentially impacting ABBVIE's revenue from this product segment as generic alternatives could enter the market.
Company
ABBVIE INC (ABBV)NYSE — Healthcare: Manufacturing, Drug Manufacturers - General: Pharmaceutical Preparations
www.abbvie.comSimilar Events
Patent Expiration for US9499545 related to UBRELVY
Patent US9499545, related to the migraine treatment drug UBRELVY, is set to expire on November 10, 2031. This patent concerns piperidinone carboxamide azaindane derivatives, which act as antagonists of CGRP receptors, and are valuable in treating conditions associated with CGRP, such as migraines. As the expiration date approaches, generic competition may potentially impact the market for UBRELVY, affecting the financial outlook for Merck Sharp and Dohme LLC and AbbVie Inc.
Patent ExpirationExpiration of Patent US11925709 for UBRELVY
Merck Sharp and Dohme LLC and AbbVie Inc.'s patent US11925709 for UBRELVY, a medication designed to aid in the rapid disintegration of a drug compound within a polymer matrix, is set to expire on January 30, 2035. This expiration could have significant commercial implications, potentially allowing generic versions of the drug to enter the market, thereby affecting the revenue streams of both companies involved. The patent underscores the formulation's effectiveness in managing the active pharmaceutical ingredient (API).
Patent ExpirationExpiration of Patent US12220408 for UBRELVY
The patent US12220408 for UBRELVY, a medication developed for the acute treatment of migraines, is set to expire on January 30, 2035. This patent, associated with Merck Sharp and Dohme LLC and AbbVie Inc., covers methods of administering ubrogepant, including considerations for patients with hepatic or renal impairment. The expiration of this patent may allow for the entry of generic versions of UBRELVY into the market, potentially impacting sales for the original product and influencing competitive dynamics in the migraine treatment sector.
Patent ExpirationExpiration of Patent US8754096 for UBRELVY
The patent US8754096 for UBRELVY, assigned to Merck Sharp and Dohme LLC and AbbVie Inc, is set to expire on July 19, 2032. UBRELVY is a medication that features piperidinone carboxamide azaindane derivatives as its active compounds, which act as antagonists of CGRP receptors, playing a significant role in the treatment or prevention of migraine and related diseases. The expiration of this patent may lead to increased competition in the migraine treatment market, potentially affecting the financial performance of the involved companies.
Patent ExpirationExpiry of Patent US8912210 for UBRELVY
Patent US8912210 related to UBRELVY, a CGRP receptor antagonist used for migraine treatment, is set to expire on December 23, 2033. The patent, held by Merck Sharp and Dohme LLC and AbbVie Inc., is crucial for the product's market exclusivity and its expiration may lead to increased competition, potentially affecting pricing and market share for UBRELVY.
Patent ExpiryPatent Expiration for AUVELITY (US11925636)
The patent related to AUVELITY (US11925636) assigned to Axsome Therapeutics Inc. and Antecip Bioventures II LLC will expire on January 20, 2043. AUVELITY is a formulation that includes bupropion and dextromethorphan designed to treat various nervous system conditions, including depression and anxiety, without significant dose dumping in the presence of ethanol. The expiration of this patent may increase market competition for AUVELITY by enabling the entry of generic versions, potentially impacting Axsome Therapeutics' revenue and market share.
Patent ExpirationPatent Expiration for VEKLURY - US8318682
Gilead Sciences Inc's patent US8318682 for VEKLURY, which relates to a class of nucleoside compounds useful in treating Flaviviridae virus infections, especially hepatitis C, is set to expire on April 22, 2029. This expiration could impact Gilead's exclusivity in the market and open the door for generic competition, affecting future revenue from VEKLURY.
Patent EventPatent Expiration: QELBREE (US11458143)
The patent for QELBREE (US11458143), related to a treatment for ADHD using a pharmaceutical agent that acts on serotonergic and noradrenergic reuptake transporters and monoamine receptors, will expire on September 4, 2029. This expiration could lead to increased competition from generics, impacting Supernus Pharmaceuticals Inc.'s revenue from this product.
Patent ExpirationPatent Expiration for AUVELITY (US12036191)
The patent US12036191 for AUVELITY, assigned to Axsome Therapeutics Inc and Antecip Bioventures II LLC, is set to expire on February 15, 2043. AUVELITY is designed to treat nervous system and psychiatric conditions, including major depressive disorder, using a combination of dextromethorphan and bupropion, specifically for patients with certain metabolizer genotypes. The expiration of this patent may affect the companies' intellectual property rights and market position, potentially allowing for generic competition in the market.
patent expiration